Terms: = Leukemia AND LMO2, RBTN2, 4005, ENSG00000135363, P25791, TTG2, RBTNL1, RHOM2 AND Treatment
30 results:
1. A case of T-cell acute lymphoblastic leukemia in retroviral gene therapy for ADA-SCID.
Cesana D; Cicalese MP; Calabria A; Merli P; Caruso R; Volpin M; Rudilosso L; Migliavacca M; Barzaghi F; Fossati C; Gazzo F; Pizzi S; Ciolfi A; Bruselles A; Tucci F; Spinozzi G; Pais G; Benedicenti F; Barcella M; Merelli I; Gallina P; Giannelli S; Dionisio F; Scala S; Casiraghi M; Strocchio L; Vinti L; Pacillo L; Draghi E; Cesana M; Riccardo S; Colantuono C; Six E; Cavazzana M; Carlucci F; Schmidt M; Cancrini C; Ciceri F; Vago L; Cacchiarelli D; Gentner B; Naldini L; Tartaglia M; Montini E; Locatelli F; Aiuti A
Nat Commun; 2024 Apr; 15(1):3662. PubMed ID: 38688902
[TBL] [Abstract] [Full Text] [Related]
2. ZNF683 marks a CD8
Parry EM; Lemvigh CK; Deng S; Dangle N; Ruthen N; Knisbacher BA; Broséus J; Hergalant S; Guièze R; Li S; Zhang W; Johnson C; Long JM; Yin S; Werner L; Anandappa A; Purroy N; Gohil S; Oliveira G; Bachireddy P; Shukla SA; Huang T; Khoury JD; Thakral B; Dickinson M; Tam C; Livak KJ; Getz G; Neuberg D; Feugier P; Kharchenko P; Wierda W; Olsen LR; Jain N; Wu CJ
Cancer Cell; 2023 Oct; 41(10):1803-1816.e8. PubMed ID: 37738974
[TBL] [Abstract] [Full Text] [Related]
3. lmo2 promotes the development of AML through interaction with transcription co-regulator LDB1.
Lu L; Wang J; Fang F; Guo A; Jiang S; Tao Y; Zhang Y; Li Y; Zhang K; Zhang Z; Zhuo R; Chu X; Li X; Tian Y; Ma L; Sang X; Chen Y; Yu J; Yang Y; Cao H; Gao J; Lu J; Hu S; Pan J; He H
Cell Death Dis; 2023 Aug; 14(8):518. PubMed ID: 37573405
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic utility of key copy number alterations in T cell acute lymphoblastic leukemia.
Kumari S; Ali MS; Singh J; Arora M; Verma D; Pandey AK; Benjamin M; Bakhshi S; Palanichamy JK; Sharma A; Singh I; Tanwar P; Singh AR; Pushpam D; Qamar I; Chopra A
Hematol Oncol; 2022 Oct; 40(4):577-587. PubMed ID: 35644022
[TBL] [Abstract] [Full Text] [Related]
5. [High Expression Level of SP1, CSF1R, and PAK1 Correlates with Sensitivity of leukemia Cells to the Antibiotic Mithramycin].
Vagapova ER; Lebedev TD; Tikhonova AD; Goikhman BV; Ivanenko KA; Spirin PV; Prassolov VS
Mol Biol (Mosk); 2020; 54(3):522-528. PubMed ID: 32492016
[TBL] [Abstract] [Full Text] [Related]
6. lmo2 Confers Synthetic Lethality to PARP Inhibition in DLBCL.
Parvin S; Ramirez-Labrada A; Aumann S; Lu X; Weich N; Santiago G; Cortizas EM; Sharabi E; Zhang Y; Sanchez-Garcia I; Gentles AJ; Roberts E; Bilbao-Cortes D; Vega F; Chapman JR; Verdun RE; Lossos IS
Cancer Cell; 2019 Sep; 36(3):237-249.e6. PubMed ID: 31447348
[TBL] [Abstract] [Full Text] [Related]
7. PI3Kγ/δ and NOTCH1 Cross-Regulate Pathways That Define the T-cell Acute Lymphoblastic leukemia Disease Signature.
Efimenko E; Davé UP; Lebedeva IV; Shen Y; Sanchez-Quintero MJ; Diolaiti D; Kung A; Lannutti BJ; Chen J; Realubit R; Niatsetskaya Z; Ten V; Karan C; Chen X; Califano A; Diacovo TG
Mol Cancer Ther; 2017 Oct; 16(10):2069-2082. PubMed ID: 28716817
[TBL] [Abstract] [Full Text] [Related]
8. lmo2 Enhances Lamellipodia/Filopodia Formation in Basal-Type Breast Cancer Cells by Mediating ARP3-Profilin1 Interaction.
Liu Y; Wu C; Zhu T; Sun W
Med Sci Monit; 2017 Feb; 23():695-703. PubMed ID: 28170369
[TBL] [Abstract] [Full Text] [Related]
9. The oncofusion protein FUS-ERG targets key hematopoietic regulators and modulates the all-trans retinoic acid signaling pathway in t(16;21) acute myeloid leukemia.
Sotoca AM; Prange KH; Reijnders B; Mandoli A; Nguyen LN; Stunnenberg HG; Martens JH
Oncogene; 2016 Apr; 35(15):1965-76. PubMed ID: 26148230
[TBL] [Abstract] [Full Text] [Related]
10. lmo2 at 25 years: a paradigm of chromosomal translocation proteins.
Chambers J; Rabbitts TH
Open Biol; 2015 Jun; 5(6):150062. PubMed ID: 26108219
[TBL] [Abstract] [Full Text] [Related]
11. A modified γ-retrovirus vector for X-linked severe combined immunodeficiency.
Hacein-Bey-Abina S; Pai SY; Gaspar HB; Armant M; Berry CC; Blanche S; Bleesing J; Blondeau J; de Boer H; Buckland KF; Caccavelli L; Cros G; De Oliveira S; Fernández KS; Guo D; Harris CE; Hopkins G; Lehmann LE; Lim A; London WB; van der Loo JC; Malani N; Male F; Malik P; Marinovic MA; McNicol AM; Moshous D; Neven B; Oleastro M; Picard C; Ritz J; Rivat C; Schambach A; Shaw KL; Sherman EA; Silberstein LE; Six E; Touzot F; Tsytsykova A; Xu-Bayford J; Baum C; Bushman FD; Fischer A; Kohn DB; Filipovich AH; Notarangelo LD; Cavazzana M; Williams DA; Thrasher AJ
N Engl J Med; 2014 Oct; 371(15):1407-17. PubMed ID: 25295500
[TBL] [Abstract] [Full Text] [Related]
12. LIM domain only-2 (lmo2) induces T-cell leukemia by two distinct pathways.
Smith S; Tripathi R; Goodings C; Cleveland S; Mathias E; Hardaway JA; Elliott N; Yi Y; Chen X; Downing J; Mullighan C; Swing DA; Tessarollo L; Li L; Love P; Jenkins NA; Copeland NG; Thompson MA; Du Y; Davé UP
PLoS One; 2014; 9(1):e85883. PubMed ID: 24465765
[TBL] [Abstract] [Full Text] [Related]
13. BET protein inhibition shows efficacy against JAK2V617F-driven neoplasms.
Wyspiańska BS; Bannister AJ; Barbieri I; Nangalia J; Godfrey A; Calero-Nieto FJ; Robson S; Rioja I; Li J; Wiese M; Cannizzaro E; Dawson MA; Huntly B; Prinjha RK; Green AR; Gottgens B; Kouzarides T
Leukemia; 2014 Jan; 28(1):88-97. PubMed ID: 23929215
[TBL] [Abstract] [Full Text] [Related]
14. The roles of miR-146a in the differentiation of Jurkat T-lymphoblasts.
Saki N; Abroun S; Soleimani M; Mortazavi Y; Kaviani S; Arefian E
Hematology; 2014 Apr; 19(3):141-7. PubMed ID: 23796062
[TBL] [Abstract] [Full Text] [Related]
15. [Progress in improvement of lentiviral vectors' transcriptional read-through].
He J; Zhang J
Sheng Wu Gong Cheng Xue Bao; 2011 Nov; 27(11):1541-8. PubMed ID: 22393708
[TBL] [Abstract] [Full Text] [Related]
16. Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency.
Gaspar HB; Cooray S; Gilmour KC; Parsley KL; Adams S; Howe SJ; Al Ghonaium A; Bayford J; Brown L; Davies EG; Kinnon C; Thrasher AJ
Sci Transl Med; 2011 Aug; 3(97):97ra79. PubMed ID: 21865537
[TBL] [Abstract] [Full Text] [Related]
17. Notch1 inhibition targets the leukemia-initiating cells in a Tal1/lmo2 mouse model of T-ALL.
Tatarek J; Cullion K; Ashworth T; Gerstein R; Aster JC; Kelliher MA
Blood; 2011 Aug; 118(6):1579-90. PubMed ID: 21670468
[TBL] [Abstract] [Full Text] [Related]
18. NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols.
Zuurbier L; Homminga I; Calvert V; te Winkel ML; Buijs-Gladdines JG; Kooi C; Smits WK; Sonneveld E; Veerman AJ; Kamps WA; Horstmann M; Petricoin EF; Pieters R; Meijerink JP
Leukemia; 2010 Dec; 24(12):2014-22. PubMed ID: 20861909
[TBL] [Abstract] [Full Text] [Related]
19. Effect of lmo2 protein expression on survival in chronic myeloid leukemia patients treated with imatinib mesylate.
Sonmez M; Akagun T; Cobanoglu U; Topbas M; Erkut N; Yilmaz M; Ovali E; Omay SB
Hematology; 2009 Aug; 14(4):220-3. PubMed ID: 19635185
[TBL] [Abstract] [Full Text] [Related]
20. DNA transposons for modification of human primary T lymphocytes.
Huang X; Wilber A; McIvor RS; Zhou X
Methods Mol Biol; 2009; 506():115-26. PubMed ID: 19110623
[TBL] [Abstract] [Full Text] [Related]
[Next]
